Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 4Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Genitourinary 1Breast 1

Conditions

Stomach Neoplasms 1Sarcoma 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Carboplatin 63Cisplatin 40Pemetrexed 38Drug Therapy 37osimertinib 22anlotinib 22Etoposide 20tislelizumab 17Radiotherapy 17Paclitaxel 17Surgical Procedures, Operative 16pembrolizumab 15toripalimab 14130-nm albumin-bound paclitaxel 14aflutinib 13Docetaxel 13Bevacizumab 12sintilimab 10Specimen Handling 10Magnetic Resonance Spectroscopy 10Injections 9durvalumab 8cemiplimab 8Radiosurgery 8Platinum 8PM 01183 8Immunotherapy 8atezolizumab 7Platinum Compounds 7Blood Specimen Collection 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × pemigatinib × Thoracic × Clear all
NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
30 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡